Suchergebnisse - "Specchia, Giorgina"

PubPharm (17)

1

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia : A study from the Registro Italiano LMC and Campus CML

enthalten in: Cancer | 2023

von Tiribelli, M. | Latagliata, R. | Breccia, M. | +38

2

Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study

enthalten in: Leukemia | 2021

von Breccia, M. | Pregno, P. | Castagnetti, F. | +13

3

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

enthalten in: Haematologica | 2019

von Fava, C. | Rege-Cambrin, G. | Dogliotti, I. | +42

4

Additional chromosomal abnormalities in Philadelphia-positive clone : adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

enthalten in: Blood | 2012

von Luatti, S. | Castagnetti, F. | Marzocchi, G. | +24

ErratumIn: Blood. 2013 Jun 27;121(26):5259 Cambrin, Rege [corrected to Rege-Cambrin, Giovanna]

5

Variant Philadelphia translocations : molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

enthalten in: Blood | 2011

von Marzocchi, G. | Castagnetti, F. | Luatti, S. | +23

CommentIn: Blood. 2011 Jun 23;117(25):6741-2. - PMID 21700778

6

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

enthalten in: American journal of hematology | 2010

von Visani, G. | Breccia, M. | Gozzini, A. | +12

7

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone : a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

enthalten in: Haematologica | 2010

von Palandri, F. | Castagnetti, F. | Iacobucci, I. | +17

8

Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements

enthalten in: Molecular cancer | 2010

von Albano, F. | Anelli, L. | Zagaria, A. | +7

9

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia : a European LeukemiaNet Study

enthalten in: Blood | 2009

von Baccarani, M. | Rosti, G. | Castagnetti, F. | +22

10

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase : a phase 2 trial of the GIMEMA CML Working Party

enthalten in: Blood | 2009

von Castagnetti, F. | Palandri, F. | Amabile, M. | +54